New

P4P Technology

The AI engine Fit Assessment

Beta

The company engages in pharmaceutical technology with R&D for a plant protein–based blood plasma substitute (edestin) and related products, including a dietary supplement, and has plans for initial human testing, aligning with pharma tech activity.

Blurb

P4P Technology develops a plant protein edestin‑based blood plasma substitute and offers dietary supplements for health and recovery.

HQ Location

Prague (Czechia)

Founded

2020

Employees

1 - 10

Total funding raised

$2.58M

Funding Status

Pre-Seed, January 1, 2024

P4P Technology is a pharmaceutical company developing a blood plasma substitute based on the plant protein edestin. Our mission is to make advanced treatment and nutrition more accessible by combining natural ingredients with cutting-edge technology to support health, recovery, and longevity.



We plan to begin the first human testing by the end of 2025. In parallel, we have launched the dietary supplement Bloody Vital, which uses the same protein and technology as our future IV product — and is already helping hundreds of people improve their health, hormonal balance, and long-term vitality.